HSBC Holdings plc vs Dr. Reddy's Laboratories Ltd Common Stock — how do they compare? HSBC Holdings plc trades at $94.27 (market cap $322.45B), while Dr. Reddy's Laboratories Ltd Common Stock trades at $13.01 (market cap $10.61B). The key difference: HSBC Holdings plc is far larger — about 30.4× Dr. Reddy's Laboratories Ltd Common Stock's market cap, and HSBC Holdings plc pays the higher dividend (3.99%). Which is the better fit depends on your goals — on Pluang, investors hold HSBC Holdings plc for 37 Days and Dr. Reddy's Laboratories Ltd Common Stock for 0 Days on average.
| HSBC | RDY | |
|---|---|---|
Market Cap | $322.45B | $10.61B |
Volume | 2,058,215 | 3,738,869 |
Sector | Financials | Health |
52-Week High | $107.86 | $15.38 |
52-Week Low | $65.67 | $11.38 |
Typical Hold Time | 37 Days | 0 Days |
Enterprise Value | $229.52B | $10.51B |
Dividend Yield | 3.99% | 0.65% |
Signals from Pluang's Aura AI — not financial advice
HSBC trades at $94.02, down 0.88% on the day, with a bearish technical signal and mixed earnings history including a recent Q1 2026 miss. The stock shows solid fundamentals with a P/E of 13.42 and net income margin of 34.54%, while cash flow trends indicate increased operational cash generation in 2026. Recent news highlights strategic hires and expansion in high-growth areas like technology banking and wealth management.
The outlook is cautiously optimistic given reasonable valuation and profitability, but risks include net cash outflows and bearish technical indicators. Analyst sentiment is mixed with a slight Hold bias, suggesting potential for stability with selective growth opportunities in wealth and international markets.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →Dr. Reddy's Laboratories Ltd. develops and manufactures generic medicines, active pharmaceutical ingredients (APIs), biosimilars, and over-the-counter (OTC) products, headquartered in Hyderabad, India, with therapeutic focus areas spanning gastrointestinal, cardiovascular, oncology, and dermatology.
Read more on RDY →